Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pharm Biomed Anal ; 15(6): 759-64, 1997 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-9172101

RESUMEN

A cheap simple and rapid extraction procedure followed by a UV high performance liquid chromatography (HPLC) assay is described for the simultaneous determination of morphine (M) and codeine (C) in plasma. The method is based on extraction of these opiates from plasma using reversed phase (solid phase) extractions columns followed by HPLC with UV detection at 240 nm. The extraction step provides, respectively, 85 and 80% recovery for M and C. The response of the detection system is linear for both molecules in the studied range from 50 to 750 ng ml-1. No other drugs have been found to interfere with the assay. This method offers a quick, cost effective and reliable procedure for specifically determining M and C, from a small sample volume.


Asunto(s)
Analgésicos Opioides/sangre , Cromatografía Líquida de Alta Presión , Codeína/sangre , Morfina/sangre , Humanos , Modelos Lineales , Reproducibilidad de los Resultados , Espectrofotometría Ultravioleta , Factores de Tiempo
2.
J Chromatogr B Biomed Appl ; 657(1): 233-7, 1994 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-7952075

RESUMEN

A rapid, sensitive and selective method for the quantification of zidovudine (AZT) and one of its metabolites (the 5'-glucuronyl form of zidovudine, G-AZT) in biological fluids is described, based on high-performance liquid chromatography. Solid-phase extraction on-line with chromatographic separation was used. The limit of quantitation of the assay is 10 ng/ml of plasma or urine for G-AZT and 20 ng/ml of plasma or urine for AZT.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Zidovudina/análogos & derivados , Zidovudina/sangre , Zidovudina/orina , Cromatografía Líquida de Alta Presión/estadística & datos numéricos , Humanos , Estructura Molecular , Sensibilidad y Especificidad
3.
Neuropediatrics ; 15(1): 37-42, 1984 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-6424041

RESUMEN

The purpose of this study was to compare three different modes of treatment in the prevention of relapses of febrile convulsions (Phenobarbital = PH, Sodium Valproate = SV, Placebo = PO) in a randomized therapeutic trial. The patients included in the study had shown their first generalized convulsive seizure during a bout of fever (greater than or equal to 38.5 degrees C) and were aged between 6 months and 4 years. They were subsequently followed up as outpatients, and Phenobarbital and sodium valproate levels were measured regularly to ascertain compliance with the treatment and to adjust the dosage accordingly. The patients' families were questioned with respect to the occurrence of feverish bouts and convulsive seizures during the interval between visits, as well as possible adverse reactions. An EEG was carried out yearly. Results were as follows: - 69 patients - 35 boys and 34 girls - with an average age of 24 months were divided into 3 groups according to treatment: 21 cases on PH, 22 cases on SV, and 26 cases on PO. - they were followed up for an average duration of 21 months. - the average number of feverish bouts per child and per year was evaluated at 2.5, no statistically significant difference being noticeable between the various modes of prophylaxis. - 15 relapses of febrile seizures were noted in 14 children, over an average duration of 23 months; on average, relapses occurred after 9 months; among the 14 children who had relapsed, one had been treated with SV, 4 with PH and 9 with PO, leading to estimated relapse rates of 4%, 19%, and 35% respectively. There is a statistically significant difference in the relapse rates between the treated groups (SV and PH) and the Placebo group, and a particularly significant difference between Sodium Valproate and Placebo.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Fenobarbital/uso terapéutico , Convulsiones Febriles/prevención & control , Ácido Valproico/uso terapéutico , Preescolar , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Electroencefalografía , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Placebos , Distribución Aleatoria , Recurrencia
5.
Rev Fr Mal Respir ; 9(2): 113-21, 1981.
Artículo en Francés | MEDLINE | ID: mdl-7255850

RESUMEN

After an intra-venous injection of a single dose (4.24 +/- 0.94 mg/kg) of anhydrous theophylline in 20 children aged 4 to 16 years, the pharmacokinetic characteristics (mean and standard deviation) were as follow: half life (T 1/2 6.06 +/- 2.53; apparent distribution volume (Vd) 0.585 +/- 0.148 l/kg and clearance from the body (Cl) at 0.078 +/- 0.35 l/kg/w. The absorption of anhydrous theophylline syrup, given to 13 children during an exacerbation of their asthma, was consistent, quick and complete. Two hours after a dose of 6 mg/kg, the plasma levels were 11.39 +/- 2.04 mg/litre. On seven occasions, the clinical results were good. The absorption of the tablet form of anhydrous theophylline was more irregular. A prolonged course of treatment in 20 subjects aged 4.5 to 17.2 years confirmed the wide variety of doses required to maintain plasma theophylline levels in the 10 to 20 mg/litre range. The doses required varied from 10 to 22.5 mg/kg/day. The correlation between the actual and calculated needs on the basis of theophylline clearance was poor (due to the bioavailability of the drug and the close dependent character of the clearance). Seven times, the results were good (twice mean theophylline levels below 10 mg/litre). The proposition of good results in this study is less than that reported in the literature.


Asunto(s)
Asma/tratamiento farmacológico , Teofilina/metabolismo , Adolescente , Niño , Preescolar , Femenino , Semivida , Humanos , Lactante , Cinética , Masculino , Teofilina/administración & dosificación , Teofilina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA